Helus Pharma Inc. (HELP)
NASDAQ: HELPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
HELP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $487.68M
- EPS (TTM)
- -$4.25
- Dividend yield
- None
- 52-week range
- 3.76 – 15.15
- Day range
- 6.05 – 6.73
- Volume / Avg
- 2.50M / 1.83M
- Beta
- —
- Shares outstanding
- 79.81M
52-week range
HELP stock today
Helus Pharma (HELP) closed at $6.11 on Nov 20, down 9.88% (-$0.67), versus the S&P 500's 3.70% decline. Shares are 59.7% below their 52-week high of $15.15, set on Sep 18, 2026 and 62.5% above the 52-week low of $3.76, in the middle of the past year's range. HELP is down 25.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 9.3%.
Helus Pharma has posted a net loss over the last twelve months (EPS of -$4.25), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Helus Pharma
Company profileHelus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Michael I. Halstead J.D.
- Headquarters
- Toronto, ON
- Employees
- 100
- Website
- helus.com
Analyst forecast
ForecastConsensus (11 analysts)
none
Avg. price target
$40.62+564.81%
- Strong buy 1
- Buy 10
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-1.41 vs $-0.67
- Surprise
- -110.45%
HELP news
All HELP news- Helus Pharma Q2 Loss Widens On Higher Costs; Phase 3 Depression Data Due In Q4 2026NasdaqHELP, ET
- Cybin Inc. Announces Positive Topline Results from Phase 3 APPROACH Study of HLP003Nasdaq
- Cybin Inc. Reports Second Quarter Fiscal 2027 Financial ResultsNasdaq
- Why is Helus Pharma stock tumbling today?Investing.com
- Helus Pharma Reports Second Quarter Fiscal 2027 Financial Results and Recent Business HighlightsGlobeNewswire
- Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026GlobeNewswire
- Cybin Inc. Announces Co-Founders Eric So and Paul Glavine Transition from Executive RolesNasdaq
- Helus Pharma to Participate in the Guggenheim Healthcare Innovation ConferenceGlobeNewswire
Helus Pharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| WVEWave Life Sciences Inc. | 2.56 | -5.88% | $504.91M | vs HELP |
| EVOEvotec SE ADR | 1.32 | -8.97% | $469.11M | vs HELP |
| MNPRMonopar Therapeutics Inc. | 69.00 | -1.84% | $467.60M | vs HELP |
| RZLTRezolute Inc. | 3.92 | -6.67% | $465.58M | vs HELP |
| ALMSAlumis Inc. | 3.96 | -8.54% | $514.09M | vs HELP |
| BLSMBlossomHill Therapeutics Inc. | 14.51 | +0.69% | $461.20M | vs HELP |
| GYREGyre Therapeutics Inc. | 4.21 | -6.86% | $460.79M | vs HELP |
| NGNENeurogene Inc. | 22.15 | -3.40% | $458.53M | vs HELP |
Indexes, lists and sector
Helus Pharma stock FAQ
What is Helus Pharma's stock price today?
HELP last traded at $6.11 as of Nov 20, 4:00 PM EST, down 9.88% on the day. Prices are delayed at least 15 minutes.
Does Helus Pharma pay a dividend?
No. Helus Pharma does not currently pay a regular cash dividend.
Who is Helus Pharma's CEO?
Mr. Michael I. Halstead J.D. is the chief executive officer of Helus Pharma Inc., which has about 100 employees.
Has HELP ever split its stock?
Yes. The most recent HELP stock split was a 1-for-38 split on Sep 19, 2024, one of 2 splits on record.
What is the HELP 52-week high?
The 52-week high for HELP is $15.15 and the 52-week low is $3.76. The stock is currently 59.7% below its high.